Anti-TIGIT treatments demonstrated efficacy in preclinical trials of multiple myeloma and head and neck squamous cell carcinoma (HNSCC) by decreasing tumor progression in a CD8+ T cell-dependent manner (Guillerey et al., 2018; Wu et al., 2019). This evidence concerns the gene CD8A and head and neck squamous cell carcinoma.